Urology Medical News about tolterodine extended release

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Tolterodine extended release is well tolerated in older subjects
International Journal of Clinical Practice, 08/05/09

Griebling TL et al. – The nature and frequency of adverse events (AEs) associated with tolterodine ER treatment were similar across age groups in subjects with OAB, suggesting that tolterodine ER was not associated with an increased risk of AEs in older vs. younger subjects and, thus, is a suitable first–line pharmacotherapy treatment for OAB in this population.

Methods

Retrospective analysis of pooled data from five large, randomised, double–blind, placebo–controlled trials.
Subjects with OAB symptoms, including urinary frequency and urgency (and nocturia in two studies) with or without urgency urinary incontinence, received qd treatment with tolterodine ER (4 mg) or placebo for 8–12 weeks.
Data were stratified post hoc by age group: < 65 (n = 2531), 65–74 (n = 1059) and >= 75 years (n = 573).
Tolerability was assessed by evaluating the occurrence of adverse events (AEs). AE occurrences from each study were mapped to the MedDRA coding dictionary of preferred terms.

Results

Discontinuation rates were slightly higher among subjects >= 75 years of age vs. those < 65 years of age; however, this was observed in subjects treated with placebo as well as tolterodine ER.
There were no significant differences in the occurrence of dry mouth, headache, constipation, nausea, urinary tract infection, blurred vision, dry eye, dizziness and micturition disorder in older vs. younger subjects treated with tolterodine ER relative to placebo
Dry mouth was the only AE consistently associated with tolterodine ER treatment.
The occurrence of all other AEs was ? 5% in most age and treatment cohorts.
Most AEs were mild or moderate in all age and treatment cohorts.

<< Previous
Preoperative Indications for Percutaneous Nephrolithotripsy in...

Next >>
The burden and extent of comorbid conditions in patients with...